Skip Navigation LinksHome > March 2014 - Volume 27 - Issue 3 > What are extended-spectrum beta-lactamases?
Journal of the American Academy of Physician Assistants:
doi: 10.1097/
Pharmacology Consult

What are extended-spectrum beta-lactamases?

Sutton, S. Scott PharmD, BCPS

Collapse Box


ABSTRACT: The emergence and spread of extended-spectrum beta-lactamases (ESBLs) in Gram-negative bacteria pose important challenges for clinicians, as management options for these organisms are limited. The emergence of ESBL-producing Gram-negative bacteria is one of the most significant epidemiologic changes in infectious diseases during recent years. Failure to treat with an antibiotic active against ESBL-producing organisms is associated with increased patient morbidity and mortality. Carbapenems are considered the primary antibacterials for infections caused by ESBL-producing organisms but their overuse poses significant cause for concern.

© 2014 American Academy of Physician Assistants.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.